Congenital Hyperinsulinaemic Hypoglycaemia, Octreotide Adverse Reaction
Conditions
Brief summary
To analyze and evaluate the efficacy and safety of octreotide subcutaneous injection in the treatment of diazazine-ineffective congenital hyperinsulinemia (CHI) in children.
Detailed description
Octreotide subcutaneous injection is effective and safe in the treatment of congenital hyperinsulinemia in children with inefficacy of diazazine.
Interventions
Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine
Sponsors
Beijing Children's Hospital
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Consistent with the diagnosis of congenital hyperinsulinemia with ineffective diazine; With the maximum dose of diazine at 15mg/kg/d for 5 days, fasting blood glucose/postprandial blood glucose could not be stabilized at the target value of 3.3mmol/L without intravenous glucose infusion. 2. patients treated with octreotide subcutaneous injection.
Exclusion criteria
1. Before the diagnosis of CHI and the treatment related to CHI, the child had received total pancreatectomy without octreotide 2. Secondary hypoglycemia caused by diseases other than CHI 3. Patients who refused to take octreotide due to parents or family economic reasons, but not hospital treatment factors. 4. Patients who intervene/interfere with octreotide treatment regimen for parental reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| blood glucose | 1 year | Maintain target blood glucose ≥3.3mmo/L |
Countries
China
Outcome results
None listed